Literature DB >> 20694489

Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome.

Evanthia Diamanti-Kandarakis1, Sarantis Livadas, Ilias Katsikis, Christine Piperi, Aimilia Mantziou, Mantziou Aimilia, Athanasios G Papavassiliou, Dimitrios Panidis.   

Abstract

Intriguing studies suggest that osteocalcin (OC) and its carboxylated (Gla)/uncarboxylated form are involved in the regulation of insulin secretion and action. Additionally, advanced glycated end products (AGEs) directly regulate the secretion of these osteoblast-derived molecules. In polycystic ovarian syndrome (PCOS), among the pathophysiological aberrations, deregulation of insulin secretion and action as well as elevated AGEs levels have been demonstrated. In this study, we evaluated the serum levels of osteocalcin and Gla osteocalcin and their possible associations with metabolic, hormonal, and ultrasonographic components of PSOS: 97 women were studied, 50 PCOS patients and 47 controls, matched for age and body mass index (BMI). In each subject, the levels of bone metabolism markers have been evaluated, and metabolic and hormonal profiles as well as ovarian ultrasound were carried out. Osteocalcin (4.30 ± 1.74 vs. 6.20 ± 1.78 ng/ml, P < 0.0005) values were significantly lower, whereas Gla osteocalcin (37.93 ± 6.87 vs. 9.64 ± 8.21 ng/ml, P < 0.0005) and receptor activator for nuclear factor-κB ligand (0.54 ± 0.26 vs. 0.16 ± 0.15 pmol/l, P < 0.0005) values were significantly higher in PCOS subjects compared to the control group, independently of obesity. A significant association was disclosed between osteocalcin and Gla osteocalcin with androgens, insulin resistance, AGEs, and ovarian morphology. Receiver operating curve analysis revealed that Gla osteocalcin [AUC, 0.975 (95% CI, 0.93-1.00)] as well as AGEs are significant prognostic factors of PCOS [AUC, 0.986 (95% CI, 0.97-1.00)]. Lower osteocalcin and elevated serum levels of its carboxylated form are displayed in PCOS subjects and are associated with several PCOS components. These findings suggest a potential interaction between bone-derived markers and the metabolic/hormonal abnormalities observed in PCOS. However, the pathophysiological mechanisms and moreover the possible clinical implications require further investigation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20694489     DOI: 10.1007/s00774-010-0211-2

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  21 in total

Review 1.  Reciprocal regulation of bone and energy metabolism.

Authors:  Na Kyung Lee; Gerard Karsenty
Journal:  Trends Endocrinol Metab       Date:  2008-04-11       Impact factor: 12.015

2.  A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.

Authors:  E Diamanti-Kandarakis; C R Kouli; A T Bergiele; F A Filandra; T C Tsianateli; G G Spina; E D Zapanti; M I Bartzis
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

3.  beta-Cell function: a key pathological determinant in polycystic ovary syndrome.

Authors:  Mark O Goodarzi; Stephen Erickson; Sidney C Port; Robert I Jennrich; Stanley G Korenman
Journal:  J Clin Endocrinol Metab       Date:  2004-10-26       Impact factor: 5.958

Review 4.  CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.

Authors:  Damaris Vega; Naim M Maalouf; Khashayar Sakhaee
Journal:  J Clin Endocrinol Metab       Date:  2007-09-25       Impact factor: 5.958

5.  Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts.

Authors:  Sybille Franke; Heide Siggelkow; Gunter Wolf; Gert Hein
Journal:  Arch Physiol Biochem       Date:  2007-06       Impact factor: 4.076

6.  Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice.

Authors:  Mathieu Ferron; Eiichi Hinoi; Gerard Karsenty; Patricia Ducy
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

7.  Endocrine regulation of energy metabolism by the skeleton.

Authors:  Na Kyung Lee; Hideaki Sowa; Eiichi Hinoi; Mathieu Ferron; Jong Deok Ahn; Cyrille Confavreux; Romain Dacquin; Patrick J Mee; Marc D McKee; Dae Young Jung; Zhiyou Zhang; Jason K Kim; Franck Mauvais-Jarvis; Patricia Ducy; Gerard Karsenty
Journal:  Cell       Date:  2007-08-10       Impact factor: 41.582

8.  Relationship between osteocalcin and glucose metabolism in postmenopausal women.

Authors:  Jee-Aee Im; Byung-Pal Yu; Justin Y Jeon; Sang-Hwan Kim
Journal:  Clin Chim Acta       Date:  2008-07-04       Impact factor: 3.786

9.  Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men.

Authors:  Jenny M Kindblom; Claes Ohlsson; Osten Ljunggren; Magnus K Karlsson; Asa Tivesten; Ulf Smith; Dan Mellström
Journal:  J Bone Miner Res       Date:  2009-05       Impact factor: 6.741

10.  Impaired gamma carboxylation of osteocalcin in elderly women with type II diabetes mellitus: relationship between increase in undercarboxylated osteocalcin levels and low bone mineral density.

Authors:  Toshiyuki Horiuchi; Hirohito Kazama; Atsushi Araki; Junichiro Inoue; Takayuki Hosoi; Tsuneko Onouchi; Shouichi Mizuno; Hideki Ito; Hajime Orimo
Journal:  J Bone Miner Metab       Date:  2004       Impact factor: 2.626

View more
  15 in total

1.  The effects of old, new and emerging medicines on metabolic aberrations in PCOS.

Authors:  Alexandra Bargiota; Evanthia Diamanti-Kandarakis
Journal:  Ther Adv Endocrinol Metab       Date:  2012-02       Impact factor: 3.565

2.  Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice.

Authors:  Mathieu Ferron; Marc D McKee; Robert L Levine; Patricia Ducy; Gérard Karsenty
Journal:  Bone       Date:  2011-04-29       Impact factor: 4.398

3.  In vivo analysis of the contribution of bone resorption to the control of glucose metabolism in mice.

Authors:  Julie Lacombe; Gerard Karsenty; Mathieu Ferron
Journal:  Mol Metab       Date:  2013-08-15       Impact factor: 7.422

4.  Developmental androgen excess programs sympathetic tone and adipose tissue dysfunction and predisposes to a cardiometabolic syndrome in female mice.

Authors:  Kazunari Nohara; Rizwana S Waraich; Suhuan Liu; Mathieu Ferron; Aurélie Waget; Matthew S Meyers; Gérard Karsenty; Rémy Burcelin; Franck Mauvais-Jarvis
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-04-23       Impact factor: 4.310

5.  Associations of total and undercarboxylated osteocalcin with peripheral and hepatic insulin sensitivity and β-cell function in overweight adults.

Authors:  Barbara A Gower; Norman K Pollock; Krista Casazza; Thomas L Clemens; Laura Lee Goree; Wesley M Granger
Journal:  J Clin Endocrinol Metab       Date:  2013-04-24       Impact factor: 5.958

6.  Autophagic dysfunction is improved by intermittent administration of osteocalcin in obese mice.

Authors:  B Zhou; H Li; J Liu; L Xu; Q Guo; W Zang; H Sun; S Wu
Journal:  Int J Obes (Lond)       Date:  2016-01-07       Impact factor: 5.095

Review 7.  The Relationship Between Polycystic Ovarian Syndrome, Periodontal Disease, and Osteoporosis.

Authors:  Hannah E Young; Wendy E Ward
Journal:  Reprod Sci       Date:  2020-09-10       Impact factor: 3.060

8.  GGCX and VKORC1 inhibit osteocalcin endocrine functions.

Authors:  Mathieu Ferron; Julie Lacombe; Amélie Germain; Franck Oury; Gérard Karsenty
Journal:  J Cell Biol       Date:  2015-03-09       Impact factor: 10.539

9.  Role of osteocalcin, tumor necrosis factor-alpha and adiponectin in polycystic ovary syndrome patients with insulin resistance.

Authors:  Gönül Erkan; Ahter Tanay Tayyar; Gökhan Açmaz; İptisam İpek Müderris; Gülden Başkol; Fahri Bayram
Journal:  Turk J Obstet Gynecol       Date:  2017-06-15

10.  Serum under-carboxylated osteocalcin levels in women with polycystic ovary syndrome: weight-dependent relationships with endocrine and metabolic traits.

Authors:  Carmen E Pepene
Journal:  J Ovarian Res       Date:  2013-01-22       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.